A Phase I, Multicenter, Open-label Dose Finding Study of NJH395, Administered Intravenously in Patients With Non-breast HER2+ Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 11 Jun 2019
Price : $35 *
At a glance
- Drugs NJH-395 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Novartis Pharmaceuticals
- 11 Jan 2019 Planned End Date changed from 8 Jun 2021 to 15 Jun 2021.
- 11 Jan 2019 Planned primary completion date changed from 8 Jun 2021 to 15 Jun 2021.
- 11 Jan 2019 Status changed from not yet recruiting to recruiting.